We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Genetic Mutations Located in Urothelial Carcinoma

By LabMedica International staff writers
Posted on 29 Aug 2011
Genetic tests are being designed to allow the easy, early, accurate diagnosis of bladder cancer, and developing therapies that recognize these mutations.

Whole-exome sequencing of the genomic DNA from tissue samples led to the discovery of mutation in the gene that encodes for ubiquitously transcribed tetratricopeptide repeat, X chromosome (UTX) protein. More...


A team from the University of Colorado (Denver, CO, USA) in partnership with universities in China and Denmark reports the first genetic sequencing of urothelial (transitional) carcinoma, the most prevalent type of bladder cancer. In addition, the mutations the team found are similar to those recently discovered in a host of other cancers, implying a possible common denominator in the cause of cancer in general. Specifically, in 57 of 97 patients (59%), with urothelial carcinoma, the team found mutations in genes responsible for chromatin remodeling, which is the process of packaging DNA for easy duplication during cell division.

Chromatin describes the genetic contents of a cell's nucleus including the cell's DNA and the proteins that mold its arrangement inside the cell. These proteins arrange DNA loosely so that its inner parts are accessible and available for use. In preparation for cell division, these proteins in the cell's chromatin constrict DNA into a tight package for efficient duplication. In the development of bladder cancer, the study showed that chromatin remodeling is an important link.

Dan Theodorescu, MD, PhD, director the University of Colorado Cancer Center and an author of the work, said," The discovery of mutation in the UTX gene and seven similar chromatin remodeling genes is a major step toward genetic testing and treatment of bladder cancer". UTX has been linked with histone demethylation, a potential means of regulating cellular metabolism. The study also provides the first-ever overview of the genetic basis of urothelial bladder cancer and implicates chromatin remodeling in its cause. The study was published in August 7, 2011, in Nature Genetics.

Related Links:
University of Colorado



Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Automated Staining Unit
RAL Stainer
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.